Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Molecular Methods
100%
Cervical Cancer Screening
100%
HIV+
100%
HIV in Women
100%
Molecular Assay
33%
Colposcopy
33%
Negative Predictive Value
33%
Abnormal Pap
33%
Women's Interagency HIV Study
33%
Sensitivity/specificity
33%
Cell Markers
22%
Sampling Fraction
11%
PreTect HPV-Proofer
11%
Healthcare Risk
11%
Clinically Significant
11%
Cobas HPV Test
11%
Commercially Available
11%
Oncogenic HPV
11%
Excellent Sensitivity
11%
Large Cohort
11%
Atypical Squamous Cells of Undetermined Significance (ASC-US)
11%
Health Systems
11%
ProEx C
11%
Clinical Visit
11%
Cervical Cancer
11%
Screening Assays
11%
MRNA Expression
11%
DNA Testing
11%
Cost-effective Design
11%
Hybrid Capture
11%
HPV Types
11%
DNA PCR
11%
FDA-approved Drugs
11%
Clinical Practice
11%
Colposcopy Clinic
11%
Histology
11%
Screening Method
11%
USPHS
11%
Bleeding Risk
11%
Screening Population
11%
Abnormal Pap Test
11%
MCM2
11%
Molecular Screening
11%
E7 Oncogene
11%
Pap Test
11%
New Woman
11%
New Assay
11%
Sigma Phase
11%
Ki-67
11%
Primary Screening
11%
Semi-quantitative Scoring
11%
Female Patients
11%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Cervical Cancer Screening
100%
Colposcopy
28%
Cytotechnology
14%
Papanicolaou Stain
14%
Cell Marker
14%
Health Care
7%
Health Care Cost
7%
Malignant Neoplasm
7%
Mass Screening
7%
S Phase
7%
Precancerous Condition
7%
Infection
7%
Oncogene
7%
P16
7%
Histology
7%
Diseases
7%
Biopsy Technique
7%
Messenger RNA
7%
Carcinogenesis
7%